Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
Globe Newswire•20/10/2026•08:05 ET
0
Key Highlights
- ➤47.5% mean endoscopic disease-activity reduction after 14 days in five Crohn’s patients
- ➤58.8% mean fecal-calprotectin reduction reported in the five-patient Crohn’s cohort
- ➤All five UC patients achieved clinical response after seven days; two achieved remission
- ➤Phase 2b ASCENTRA-UC enrolling approximately 204 patients across 15 mg and 30 mg doses
- ➤Phase 2a open-label Crohn’s disease study initiating for PALI-2108
Expert Statements
Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio
“The strength of these findings is the connection between drug exposure at the site of disease, biological activity in intestinal tissue and early improvement on endoscopy.”
Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio
“In patients with longstanding fibrostenotic Crohn’s disease, most of whom were receiving biologic therapy, we observed endoscopic improvement within two weeks alongside reduced intestinal inflammation.”
Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio
“Together with our UC findings, these results strengthen our confidence in advancing PALI-2108 as a once-daily oral treatment targeting both the ileum and colon.”
Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio
“The exploratory tissue-remodeling signals also provide us with a compelling rationale to investigate its potential beyond inflammation.”
Five-patient Phase 1b Crohn’s disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days
Intestinal exposure and tissue analyses strengthen the rationale for an oral, once-daily therapy targeting the ileum and colon
Get started
Create a free account to read the full story.